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206Objectives: Bilateral pulmonary artery banding with or without ductal stenting has been performed as a resus-
citative intervention for patients considered at too high risk for conventional single ventricle palliation. The
purpose of the present study was to determine the outcomes using this strategy.
Methods:We performed a retrospective review of 24 patients with single ventricle anatomy who were younger
than 3 months who had undergone bilateral pulmonary artery banding and ductal stenting or maintenance of
prostaglandin E1 from January 2007 to October 2011 at our institution. The echocardiographic, angiographic,
operative, and clinical data were reviewed. Follow-up data were available for 100% of the patients.
Results: All 24 patients (13 male patients) underwent bilateral pulmonary artery banding at a median age of
8 days (range, 2-44 days). Their gestational age was 38 weeks (range, 27-41 weeks), and their weight was
3.01 kg (range, 1.5-4.4 kg). The cardiac diagnoses included hypoplastic left heart syndrome/variant hypoplastic
left heart syndrome in 18, unbalanced atrioventricular canal in 4, and tricuspid atresia in 2. In the hypoplastic left
heart syndrome group, 9 (50%) had an intact or a highly restrictive atrial septum requiring open (n¼ 1) or trans-
catheter (n¼ 8) atrial septostomy with or without atrial stent placement (n¼ 4). Ductal stenting was performed
in 14 patients, and 10 patients were continued with prostaglandin E1. Fifteen patients (62.5%) survived to un-
dergo a Norwood procedure (n¼ 7), comprehensive stage 2 (n¼ 1), or primary cardiac transplantation (n ¼ 7).
Of the 9 who died, support was withdrawn in 5 because of a contraindication to transplantation, 1 because of
sepsis and/or multiorgan system failure, and 1 for whom palliative care was desired. Two died awaiting trans-
plantation. All 7 patients who underwent a conventional Norwood operation survived to discharge, and 6 of the
7 (85.7%) underwent bidirectional Glenn shunt placement. Of the 7 patients who underwent transplantation,
6 (85.7%) were alive at a median follow-up of 33.6 months.
Conclusions: Bilateral pulmonary artery banding with or without ductal stenting is an effective method of
resuscitation for high-risk neonates and infants with a single ventricle, allowing for reasonable survival to con-
ventional first-stage palliation or primary transplantation. (J Thorac Cardiovasc Surg 2013;145:206-14)Patients with hypoplastic left heart syndrome (HLHS),
including variant HLHS and other complex congenital car-
diac defects with functional single ventricle (SV) physiol-
ogy and systemic outflow tract obstruction continue to be
a challenge to even the most experienced congenital heart
surgeon. Although operative mortality has steadily
decreased from the time Norwood performed and reported
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The Journal of Thoracic and Cardiovascular Surgneonates undergoing first-stage Norwood palliation still
face mortality rates of 20% to 50%.2,3
Hybrid palliation consisting of bilateral pulmonary artery
(PA) banding (bPAB) and ductal stenting (DS) or a ‘‘modi-
fied’’ hybrid approach consisting of bPAB and continuation
of prostaglandin E1 (PGE1) are strategies that have been
used for the initial palliation of HLHS until second-stage
palliation is undertaken.4-6
Early success with the hybrid approach has prompted
the increasing use of this strategy for ‘‘high-risk’’ patients
with HLHS and other SV anatomy as a less-invasive
initial procedure to optimize preoperative hemody-
namics and, in turn, improve surgical outcomes.7-9
Ongoing controversy exists regarding what constitutes
‘‘high-risk’’ criteria, but these have included an intact
atrial septum (IAS) or a restrictive atrial septum (RAS),
profound metabolic acidosis or pH less than 7, renal
insufficiency/failure, moderate or greater atrioventricular
valve regurgitation (AVVR), a diminutive aorta, severe
ventricular dysfunction, low birth weight, prematurity,
preoperative cerebrovascular accident, and/or the
presence of an extracardiac syndrome.2,3 Controversyery c January 2013
Abbreviations and Acronyms
AVVR ¼ atrioventricular valve regurgitation
bPAB ¼ bilateral pulmonary artery banding
CS2 ¼ comprehensive stage 2
DS ¼ ductal stent/ductal stenting
ECMO ¼ extracorporeal membrane oxygenation
HAA ¼ hypoplastic aortic arch
HLHS ¼ hypoplastic left heart syndrome
IAS ¼ intact atrial septum
NIRS ¼ near-infrared spectroscopy
PA ¼ pulmonary artery
PaO2 ¼ partial pressure of oxygen
PDA ¼ patent ductus arteriosus
PGE1 ¼ prostaglandin E1
POD ¼ postoperative day
RAS ¼ restrictive atrial septum
SaO2 ¼ oxygen saturation
SV ¼ single ventricle
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Dcontinues regarding the optimal timing and appropriate
choice for the second-stage procedure.
At Children’s Medical Center (Dallas, Tex), we have
performed bPAB and DS or continuation of PGE1 in our
‘‘high-risk’’ neonates and infants with HLHS or other SV
physiology with systemic outflow tract obstruction for
resuscitation and stabilization of these challenging patients
as a bridge to conventional Norwood palliation or primary
cardiac transplantation when absolute contraindications to
Norwood palliation are present.METHODS
Study Design
We performed a retrospective review of all patients with anatomic or
functional SV anatomy who were younger than 3 months and who under-
went bPAB and DS or maintenance of PGE1 from January 2007 to October
2011 at Children’s Medical Center. All clinical, echocardiographic, angio-
graphic, and operative data were reviewed. The heart rate, systolic,
diastolic, and mean blood pressure, oxygen saturation (SaO2), partial pres-
sure of oxygen (PaO2), head and flank near-infrared spectroscopy (NIRS),
arteriovenous oxygen difference (using the NIRS data as a surrogate for
mixed venous saturation), hemoglobin, lactate, net fluid balance, urine out-
put, serum creatinine, and base deficit recorded immediately before bPAB,
24 hours after bPAB, and 4 days after bPAB. Patients receiving extracorpo-
real membrane oxygenation (ECMO) support (n ¼ 4; 2 before bPAB and
2 after bPAB) were excluded from the analysis of the hemodynamic, labo-
ratory, and fluid balance data. The risk factors for hospital death were
assessed. Follow-up was complete for all 24 patients (100%).
Definitions
Patients who died before hospital discharge (including those awaiting
transplantation) orwithin 30days of bPABwere designated as hospital deaths
according to the Society ofThoracic SurgeonsNationalDatabase criteria. Pa-
tients listed for cardiac transplantationwhowere inactivated (UnitedNetwork
for Organ Allocation status 7) and died within 6 months of listing were con-
sidered ‘‘wait list mortalities’’ and also designated as hospital deaths.The Journal of Thoracic and CaA restrictive atrial septum (RAS) was defined as a color flow jet width of
3 mm or less across the interatrial septum on the echocardiogram.10 Ven-
tricular dysfunction and AVVR were graded as mild, moderate, or severe
according to the echocardiographic data. Renal failure was defined as
anuria or the need for dialysis. Renal insufficiency was defined as oliguria
with an increasing creatinine.
Management of IAS or RAS
For neonates with an IAS or RAS diagnosed prenatally, rapid planned
transfer from the delivery room to the cardiac catheterization laboratory
for emergent radiofrequency perforation or transseptal puncture, balloon
atrial septostomy, and atrial stent placement (premounted Genesis stent),
in appropriate patients, was undertaken. For those with a postnatal diagno-
sis of IAS or RAS, similar procedures were performed immediately after
the echocardiographic diagnosis.
Operative Technique for bPAB
bPAB procedures were performed in the operating room or cardiac cath-
eterization laboratory (when DS performed simultaneously) with the patient
under general anesthesia. After standard median sternotomy and minimal
branchPAmobilization, 3.5-mmGore-Texgraftswere sectioned and secured
around the left and right branch PAs to achieve a 10- to 15-mmHg increase in
blood pressure, 10% to 15% decrease in oxygen SaO2, and 10- to 15-mmHg
decrease inPaO2. The right PAbandwas positioned laterally to the ascending
aorta. The bandswere affixed to the adventitia of the respective branchPAs to
preventmigration. Small hemoclips clipswere applied for radiographic iden-
tification of thebanding sites. Intracardiac lines, pacingwires, and an abdom-
inal drain were placed. The sternum was closed, unless the patients had
significant intraoperative dysrhythmias or anasarca.
Catheterization Technique for DS Placement
The DS procedures were performed in the cardiac catheterization labo-
ratory with the patient under general anesthesia. After obtaining percutane-
ous femoral access, the patent ductus arteriosus (PDA) was crossed
antegrade with a guidewire over which either a self-expanding or pre-
mounted stent was advanced and deployed to position the stent within the
full length of the PDA. For patients who underwent simultaneous bPAB
and DS placement, direct transpulmonary DS placement was performed
using a 6F sheath inserted through a 5-0 Prolene purse-string suture.
Aortic Arch Reconstruction, DS Removal, and PA
Debanding During Surgical Palliation and
Transplantation
At the Norwood procedure or comprehensive stage 2 (CS2) palliation,
after beginning cardiopulmonary bypass, the DS was divided between
the hemoclips. The proximal stent was removed from the main PA, and
the distal main PA was either oversewn primarily or closed with a patch
of autologous pericardium, if necessary. Using selective cerebral perfusion
and after cardioplegic arrest, the distal stent was removed from the proxi-
mal descending aorta and the area s debrided to normal tissue to prevent
aortic dissection. Standard neoaortic arch reconstruction was undertaken
using a pulmonary homograft.
For patients undergoing primary transplantation, an end-to-end donor
descending thoracic aortic to recipient descending thoracic aortic anasto-
mosis was performed. A recipient brachiocephalic button or ‘‘island’’-to-
donor transverse arch anastomosis using selective cerebral perfusion was
performed, as previously described.11
The PA bands were removed, and all adventitial scar tissue was sharply
excised. The branch PAs were assessed by both visual inspection and cali-
brated vascular dilators. When indicated, branch pulmonary arterioplasty
was performed using pulmonary homograft, donor PA, or donor
pericardium.rdiovascular Surgery c Volume 145, Number 1 207
TABLE 1. Patient demographics and ‘‘high-risk’’ criteria (n ¼ 24)
Variable Patients (n)
Patient demographics
Gender (% male) 13 (54.2%)
Gestational age (wk) 38 (27-41)
Birth weight (kg) 3.02 (0.9-4.1)
Age at bPAB (wk) 8 (2-44)
Weight at bPAB (kg) 3.01 (1.5-4.4)
Prenatal diagnosis 11 (45.8%)
Extracardiac syndrome (all) 7 (29.2%)
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DStatistical Analysis
Continuous variables are presented as the mean standard deviation or
median and range. Dichotomous variables are presented as the count and
percentages. The categorical data were compared using Fisher’s exact
test or the chi-square test, as appropriate. The Student t test was used to
screen the risk factors for hospital death. A mixed model was used to com-
pare the baseline values to the post-bPAB values at 24 hours and 4 days
postoperatively. Analysis was performed with SAS software (SAS Insti-
tute, Cary, NC).
The institutional review board at Children’s Medical Center approved
the present study, and the need for patient consent was waived.Heterotaxy 4
Other 3
PDA stent 14 (58.3%)
PGE1 infusion 10 (41.7%)
High-risk criteria
Birth weight<2.5 kg 4 (16.7%)
Gestational age 36 wk 6 (25%)
Intact/restrictive atrial septum 9 (37.5%)
HLHS/variant HLHS 9/18 (50%)
Preoperative metabolic acidosis
pH<7.2 7 (29.2%)
pH<7.0 5 (20.1%)
Preoperative AV valve regurgitation* 7 (29.2%)
Preoperative renal insufficiency/failurey 6 (25%)
Preoperative severe ventricular dysfunction 5 (20.1%)
Preoperative cardiac arrest 3 (12.5%)
Preoperative CVA or seizures 2 (8.3%)
Preoperative ECMO support 2 (8.3%)
Data presented asmedian (range) or n (%). bPAB, Bilateral pulmonary artery banding;
PDA, patent ductus arteriosus; PGE1, prostaglandin E1; HLHS, hypoplastic left heart
syndrome; AV, atrioventricular; CVA, cerebrovascular accident; ECMO, extracorpo-
real membrane oxygenation. *Preoperative AV regurgitation graded at least moderate
from echocardiographic findings. yRenal insufficiency defined as oliguria with
increasing creatinine; renal failure defined as anuria and/or need for hemodialysis.RESULTS
A total of 24 consecutive patients (13 male patients,
54.2%) underwent bPAB with maintenance of ductal
patency by either DS (n ¼ 14) or PGE1 infusion (n ¼ 10)
during the study period. Two patients who presented in ex-
tremis underwent ECMO cannulation and bPAB at the
ECMO decannulation. The sternum was closed in all but
6 patients (2 after ECMO decannulation and bPAB, 2
with anasarca, and 2 with intraoperative dysrhythmias).
The patient demographics, including the ‘‘high-risk’’ cri-
teria, are listed in Table 1. The predominant cardiac diagno-
sis in the study group was HLHS or variant HLHS, present
in 18 patients (75%). Of the remaining 6 patients, 4 had an
unbalanced atrioventricular canal and 2 had tricuspid atre-
sia, d-transposition of the great arteries, and systemic
outflow tract obstruction. The anatomic and subtype classi-
fication are presented in Table 2.
An IAS or RAS was present in 50% of the HLHS/variant
HLHS group (9/18). Open atrial septostomy was performed
at ECMO cannulation in a patient with HLHS and IAS who
presented in extremis at 12 hours of life after cardiac arrest at
a remote hospital. The remaining 8 patients underwent emer-
gent transcatheter balloon atrial septostomy byway of radio-
frequencyperforation or transseptal puncture, as appropriate.
Atrial stents were placed in 4 neonates, 2with IAS and 2with
RAS, whose atrial septum was markedly thickened.
DS was performed in patients who were not considered
suitableNorwood candidates and/or forwhomprimary trans-
plantation was considered (severe AVVR, severe ventricular
dysfunction, renal failure, Scimitar syndrome, or prematurity
with respiratory distress syndrome). DS was performed
simultaneously with bPAB in 7 patients, after bPAB in 6 pa-
tients, and before bPAB in 1 neonate who presented with
a late diagnosis of HLHS, including a restrictive PDA with
suprasystemic PA pressures at nearly 2 weeks of age.Hemodyamic, Fluid Balance, and Laboratory Values
After bPAB
After bPAB, a decrease occurred in the heart rate at 24
hours that became statistically significant by postoperative
day (POD) 4 (P ¼ .005; Table 3). Also, a significant
increase was seen in the systolic, diastolic, and mean blood208 The Journal of Thoracic and Cardiovascular Surgpressure at 24 hours that persisted at 4 days postoperatively
(P<.001).
As would be expected, both SaO2 and PaO2 were lower at
24 hours and 4 days after bPAB. Head NIRS was signifi-
cantly greater at 24 hours (P<.01) but not different from
the pre-bPAB values at POD 4. No significant difference
was found in the flank NIRS at either point. Using head
NIRS as a surrogate for mixed venous saturation, a signifi-
cant decrease was seen in the arteriovenous oxygen differ-
ence at both points (P< .001). This difference was also
observed when using flank NIRS as a surrogate, implicating
a decreased SaO2 as predominantly responsible.
Although no difference was seen in the net fluid balance
within the first 24 hours after bPAB, by POD 4, the differ-
ence was significant (P<.0001). Similarly, although no dif-
ference was observed at 24 hours, a trend was seen toward
an increased urine output noted by POD 4 (P ¼ .078).
The serum creatinine and lactate levels were not different
at 24 hours; however, by POD 4, they had decreased signif-
icantly (P<.001, P ¼ .048). Similarly, the base excess was
unchanged at 24 hours yet had significantly improved by
POD 4 (P ¼ .016). An increase occurred in serumery c January 2013
TABLE 2. Anatomic and subtype classification (n ¼ 24)
Classification Patients (n)
HLHS 14
MS/AS 9
MS/AA 3
MA/AA 2
Variant HLHS 4
MA/AS/VSD with type B IAA 1
Heterotaxy with mesocardia and primitive SV,
unobstructed TAPVC, RAAwith vascular ring,
interrupted IVC
1
Dextrocardia with HLV, LVOT hypoplasia, and
straddling TV
1
DORV/MAwith AS 1
Unbalanced AVC 4
RV-dominant RAA, vascular ring, bilateral SVC 1
RV-dominant CoA, unobstructed TAPVC 1
RV-dominant Ao atresia, HAA, LCA from right PA,
PAPVC/Scimitar syndrome
1
LV-dominant CoA, HAA 1
Tricuspid atresia with d-TGA and LVoutflow
tract obstruction
2
HLHS, Hypoplastic left heart syndrome; MS, mitral stenosis; AS, aortic stenosis;
AA, aortic atresia;MA, mitral atresia; VSD, ventricular septal defect; IAA, interrupted
aortic arch; SV, single ventricle; TAPVC, total anomalous pulmonary venous connec-
tion; RAA, right aortic arch; IVC, inferior vena cava; HLV, hypoplastic left ventricle;
LVOT, left ventricular outflow tract; TV, tricuspid valve; DORV, double outlet right
ventricle; AVC, atrioventricular canal; RV, right ventricle; SVC, superior vena cava;
Ao, aorta; LCA, left coronary artery; PA, pulmonary artery; PAPVC, partial anoma-
lous pulmonary venous connection; CoA, coarctation; HAA, hypoplastic aortic
arch; d-TGA, d-transposition of the great arteries; LV, left ventricular.
TABLE 3. Hemodynamic, fluid balance, and laboratory variables*
Variable
Before
bPAB
24-h After
bPAB
4 d After
bPAB
HR (beats/min) 153  14 148  14 143  13y
SBP (mm Hg) 66  11 72  9z 78  12x
DBP (mm Hg) 35  6 41  5x 40  5y
MAP (mm Hg) 46  6 53  5x 54  7x
SaO2 (%) 92  5 82  4x 83  4x
PaO2 (mm Hg) 57  12 43  4x 44  5x
NIRS head (%) 56  10 63  9z 59  10
NIRS flank (%) 60  12 63  12 60  13
Arteriovenous oxygen
difference (%)
Head NIRS 36  10 19  9x 24  12x
Flank NIRS 31  13 19  12x 23  14y
Net intake/output balance (mL) 533  622 458  572 170  676x
Urine output (mL/kg/h) 3.7  1.7 4.3  1.8 4.7  2.4
Creatinine (mg/dL) 1.1  0.7 0.9  0.7 0.7  0.4x
pH 7.36  0.06 7.36  0.06 7.38  0.08
Lactate (mg/dL) 2.3  1.6 2.1  2.2 1.4  0.3y
Base excess (mEq/L) 0.7  4.6 0.1  3.6 3.9  4.4y
Hemoglobin (g/dL) 14.5  1.7 15.5  1.8y 14.7  1.5
bPAB, Bilateral pulmonary artery banding; HR, heart rate; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure; MAP, mean arterial pressure; SaO2, oxygen
saturation; PaO2, partial pressure of oxygen; NIRS, near-infrared spectroscopy;
ECMO, extracorporeal membrane oxygenation. *Patients receiving ECMO support
(n ¼ 4, 2 before and 2 after bPAB) were excluded from analysis. yP < .01.
zP<.05. xP<.001.
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blood transfusions given. The serum pH was not different
at any point.FIGURE 1. Outcomes after bilateral pulmonary artery banding in high-
risk single ventricle patients. TXPLT, Transplant or transplantation; BDG,
bidirectional Glenn shunt; WL, wait list.Survival to Surgical Palliation or Primary
Transplantation
Of the 24 patients, 15 (62.5%) survived to conventional
Norwood (n ¼ 7; Blalock-Taussig shunt in 5, Sano shunt
in 2), CS2 (n ¼ 1), or primary transplantation (n ¼ 7;
Figure 1).
The median time to the Norwood procedure was 7 days
(range, 4-78 days). One Norwood procedure performed at
78 days was in an infant with trisomy 21 and an unbalanced
atrioventricular canal with coarctation/transverse arch
hypoplasia for whom a 2-ventricle repair was planned but
not performed given the complex atrioventricular valve
anatomy.
One infant, who was readmitted from home, underwent
CS2 palliation 118 days after bPAB/PDA stent placement.
Nine patients with contraindications to Norwood (severe
AVVRwith or without severe ventricular dysfunction) were
listed for primary transplantation. Seven patients (77.7%)
underwent successful transplantation at a median of 89
days (range, 21-201 days) after bPAB.The Journal of Thoracic and CaHospital Deaths
There were 9 hospital deaths (37.5%). Of these 9
patients, 3 experienced cardiac arrest within hours of
bPAB, 2 of whom underwent emergent ECMO cannulation
without meaningful cardiac recovery. Of the 3, 2 (including
a former 33-week, 2.3-kg neonate) had a diminutive ascend-
ing aorta less than 1.5 mm and decompensated from coro-
nary ischemia, presumed related to coronary distortion
by the DS. The third patient (former 33-week, 1.8-kg
patient with respiratory distress syndrome) experiencedrdiovascular Surgery c Volume 145, Number 1 209
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acidosis. Support was withdrawn in 3 neonates with abso-
lute contraindications to transplantation (chronic renal fail-
ure in 1, Scimitar syndrome or a hypoplastic right lung in 1,
and uncontrolled sepsis in 1). One neonate discharged with
palliative care per the family’s request died at home several
days later. Finally, support was withdrawn in 2 infants
awaiting transplantation that was inactivated after they
developed contraindications to transplantation (recurrent
sepsis with renal failure in 1 and chronic lung disease in 1).
Risk Factors for Death
Gestational age, the presence of IAS or RAS, extracar-
diac syndrome (including heterotaxy), age at bPAB, age
at the Norwood operation, CS2, or transplantation, preoper-
ative profound metabolic acidosis, moderate or greater
AVVR, poor ventricular function, renal insufficiency or
renal failure, cardiac arrest, neurologic deficit, ECMO sup-
port, or strategy to maintain ductal patency (PGE1 vs DS)
were not associated with any significant increased risk of
hospital death. Although the birth weight had a borderline
association with hospital death (P¼ .055), no patient whose
birth weight was less than 2.5 kg (n ¼ 4) survived.
Follow-up
The median follow-up period for those who survived
bPAB and DS or PGE1 was 1.58 years (range, 0.34-4.36
years), and the follow-up data were complete in all.
Of the 7 patients surviving Norwood palliation, 6
(85.7%) subsequently underwent bidirectional cavopulmo-
nary (Glenn) shunt, 2 of whom (33.3%) required subse-
quent left PA angioplasty or stent placement.
Of the 7 patients undergoing primary transplantation, 6
(85.7%) were alive at a median follow-up of 33.6 months.
Of these 7 patients, 4 (57.1%) underwent pulmonary arte-
rioplasty at transplantation (3 bilateral and 1 right PA) but
underwent no additional PA interventions. One patient
transplanted 3 years previously underwent balloon angio-
plasty at 1 month and 1 year after transplantation with
a good angiographic result.
Late Deaths
The patient characteristics and outcomes for the entire
cohort are listed in Table 4. There were 4 late deaths (4/
15, 26.6%). One death occurred 3 months after primary
transplantation in 1 patient who presented in extremis
with HLHS and IAS requiring emergent ECMO support.
She was found to have left PA stenosis (stent placed) and
right-sided pulmonary vein stenosis at cardiac catheteriza-
tion, immediately after which she developed pulmonary
hemorrhage and worsening respiratory failure, from which
she died.
One patient with HLHS and RAS developed respiratory
failure 1 month after CS2, secondary to influenza B and210 The Journal of Thoracic and Cardiovascular Surgthe development of branch PA thrombosis. Despite antico-
agulation and aggressive catheter-based and surgical pul-
monary thrombectomy, she died.
One death occurred secondary to RSV bronchiolitis
2.5 years after a Glenn shunt procedure in a patient with tri-
somy 21.
Finally, 1 interstage death occurred at home in an infant
with HLHS and mosaic Turner syndrome 2 months after
a Norwood procedure and is presumed secondary to
aspiration.
DISCUSSION
HLHSwas a uniformly fatal condition until the Norwood
procedurewas first developed in the 1970s and cardiac trans-
plantation was introduced in the 1980s. Additional modifi-
cation of first-stage palliation occurring in the 1990s and
into the new millennium has allowed for improved surgical
survival.1,4,12 In the present era, the operative mortality for
the Norwood procedure, now also applied to a variety of
complex congenital cardiac defects with a functional SV
and associated systemic outflow tract obstruction, has been
reported to be as low as 10% to 20% in specialized
centers.13,14 Greater operative mortality has been reported
for patients with an IAS or highly RAS, preoperative
shock with profound metabolic acidosis or pH less than 7,
renal failure, a diminutive or small ascending aorta,
prematurity, low birth weight, ventricular dysfunction,
significant AVVR, and/or the presence of extracardiac and
chromosomal disorders, not only for patients undergoing
reconstructive surgical palliation, but also for those
awaiting cardiac transplantation.7,15-18
A reduction of pulmonary blood flow by PA banding was
first reported by Gibbs and colleagues19 as an alternative to
a Norwood procedure in newborns. This strategy has since
been expanded to other forms of SV and even 2-ventricle
anatomy in an attempt to optimize severe Qp/Qs imbalance
that might otherwise lead to multiorgan system dysfunction
from which recovery might not be possible.20-22
The presence of multiorgan system dysfunction before
planned surgical intervention can lead to additional organ
impairment from cardiopulmonary bypass and a period of
circulatory arrest. Pharmacologic manipulation and ventila-
tory maneuvers might be inadequate in the common sce-
nario of hypotension and markedly elevated systemic
vascular resistance. Mechanical limitation of pulmonary
blood flow, in concert with augmentation of systemic perfu-
sion, must be achieved.
In the present series, bPAB was performed to limit
mechanically systolic pulmonary flow and diastolic runoff
into the pulmonary circulation when attempts at pharmaco-
logicmanipulation and ventilatory strategies failed to restore
effective systemic perfusion. Shortly after bPAB, significant
improvement was seen in systemic perfusion, as evidenced
by expected increases in the systolic, diastolic, and meanery c January 2013
TABLE 4. Patient characteristics and outcomes
Pt.
no. Diagnosis
Birth
weight
(kg)
Gestational
age (wk)
Fetal
diagnosis IAS/RAS
Moderate
or greater
AVVR RI/RF
Poor
function
Extracardiac
syndrome Outcome
1 HLHS 3.8 39 No IAS No Yes Yes No Transplantation, late death
2 HLHS 3.7 39 No — Yes Yes No No Hospital death
3 HLHS 2.9 39 No RAS No No No No CS2, late death
4 HLHS 3.0 37 Yes RAS Yes No No No Hospital death
5 Unbalanced AVC 3.1 40 Yes — No No No Heterotaxy Transplantation
6 HLHS 1.8 33 Yes — No No No No Hospital death
7 HLHS variant 3.4 36 No — No No Yes No Transplantation
8 HLHS 3.9 38 No IAS No Yes No No Transplantation
9 Unbalanced AVC 3.0 37 Yes — Yes No No Trisomy 21 Norwood/BTS, late death
10 HLHS 2.3 33 No — Yes No Yes No Hospital death (WLmortality)
11 HLHS 3.4 37 Yes — No Yes No No Hospital death (WLmortality)
12 TA, d-TGA, LVOTO 1.6 35 No — No No No Heterotaxy Hospital death
13 HLHS variant 3.3 38 No — Yes No Yes Heterotaxy Transplantation
14 Unbalanced AVC 3.3 40 No — No No No Heterotaxy Hospital death
15 HLHS variant 3.2 38 No — Yes No No No Transplantation
16 HLHS 3.2 39 Yes RAS No No No No Norwood/Sano
17 HLHS variant 3.2 39 No RAS No Yes No Other Hospital death (palliative
care)
18 HLHS 3.4 40 Yes RAS No No No No Norwood/Sano
19 TA, d-TGA, LVOTO 0.9 27 No — No No No No Hospital death
20 HLHS 3.4 40 Yes IAS No No No No Norwood/BTS
21 HLHS with PAPVC 2.9 36 Yes — No Yes No No Norwood/BTS
22 HLHS 4.1 38 No RAS No No No No Norwood/BTS
23 Unbalanced AVC 3.7 39 Yes — Yes No No No Transplantation
24 HLHS 3.0 41 No — No No Yes Turner’s (mosaic) Norwood/BTS, late death
Pt. no., Patient number; AVVR, atrioventricular valve regurgitation; IAS, intact atrial septum; RAS, restrictive atrial septum; RI, renal insufficiency; RF, renal failure; HLHS, hy-
poplastic left heart syndrome; AVC, atrioventricular canal;CS2, comprehensive stage 2; BTS, Blalock-Taussig shunt;WL, wait list; TA, tricuspid atresia; d-TGA, d-transposition of
the great arteries; LVOTO, left ventricular outflow tract obstruction; PAPVC, partial anomalous pulmonary venous connection.
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resultant improvement in the arteriovenous oxygen differ-
ence, net fluid balance, and urine output), and improvement
in serum creatinine, lactate, and base excess over time. This
beneficial effect provided the necessary conditions for
the recovery of organ dysfunction, allowing for CS2 in 1
patient, a conventional Norwood operation in 7 patients
(our preferred approach), and primary transplantation in 7
patients in whom Norwood palliation was contraindicated.
Caldarone and colleagues23 found similar 1-year survival
in patients who underwent bPAB and PDA stenting as part of
their newly established hybrid program as a Norwood alter-
native, pretransplantation stabilization procedure, or sal-
vage procedure and those who underwent the Norwood
operation in their well established program (survival, 68%
vs 71.4%, P ¼ .56). In contrast to our study, only a small
number of ‘‘high-risk’’ or salvage patients were included.23
Although in many published series, the hybrid approach
is targeted for usual-risk patients as a Norwood alternative
or has been used for a limited number of ‘‘high-risk’’
patients, there appears to be recent heightened interest in
its application as a resuscitation strategy for this growing
and increasingly difficult subgroup.The Journal of Thoracic and CaLim and colleagues7 reported their risk-stratified ap-
proach to first-stage palliation, showing markedly improved
operative survival in 5 infants with HLHS and ‘‘high-risk’’
features (severe tricuspid regurgitation, severe right ventric-
ular dysfunction, IAS or RAS, an ascending aortic of 2 mm
or less, late presentation, weight less than 2 kg, or signifi-
cant extracardiac issues) undergoing hybrid palliation
compared with 7 infants with similar ‘‘high-risk’’ features
and 10 infants without ‘‘high-risk’’ features undergoing
the Norwood operation or Sano procedure (100% vs 29%
vs 90%, respectively).7
Sasaki and colleagues8 reported their experience with
bPAB and PGE1 in 12 ‘‘high-risk’’ patients with HLHS or
similar anomalies. Because of their concerns for high inter-
stage morbidity with ductal constriction, inadequate growth
of the ascending aorta, and the development of branch PA
stenosis in 3 patients, they suggested that early conversion
to the Norwood operation might be beneficial.8
In their recent series of 21 ‘‘high-risk‘‘ neonates, Venugo-
pal and colleagues9 reported findings somewhat similar to
those from our series. Of their 14 patients who survived
bPAB and DS, however, 9 subsequently underwent CS2
(2 died postoperatively), and 3 were able to undergordiovascular Surgery c Volume 145, Number 1 211
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Dbiventricular repair.9 In their series, no patient was bridged
to conventional Norwood or primary transplantation.9
We attempted to identify ‘‘high-risk’’ SV neonates and
intervene in a timely fashion to optimize their resuscitation
with the intent to perform early conventional Norwood pal-
liation. In those patients with significant AVVR and/or per-
sistent severe ventricular dysfunction, we used bPAB and
maintenance of ductal patency as the initial resuscitation
and later stabilization as the ‘‘bridge’’ to primary cardiac
transplantation. Not unexpectedly, the median interval to
primary transplantation was greater than 10-fold longer
than the median interval to the Norwood operation. An in-
creased frequency of branch PA intervention was associated
with a longer banding time. This is a problem with which
we are particularly attuned to in the treatment of our current
and future patients.
Birth weight less than 2.5 kg was associated with 100%
mortality in our cohort. Similarly, in other centers, birth
weight has continued to be a significant risk factor for hos-
pital death; thus, strategies to improve survival for this
‘‘highest-risk’’ group warrant additional investigation. DS
in the presence of a diminutive aorta was associated with
coronary ischemia and is not recommended.
Although not highlighted in the present analysis, opera-
tive mortality at the Norwood palliation or primary trans-
plantation for those patients successfully resuscitated with
bPAB/DS or PGE1 was comparable to that of our ‘‘usual’’
risk patients when comparing similar periods.
Owing to the relatively small number of patients in the
present series and heterogeneity at the initial presentation,
the identification of risk factors for morbidity and mortality
was a challenge. A larger prospective investigation of such
‘‘high-risk’’ neonates would be instrumental to further iden-
tify modifiable—and nonmodifiable—risk factors to opti-
mize patient selection. Improving the number of fetal
diagnoses, for example, might potentially reduce the inci-
dence of immediate postnatal cardiovascular collapse and
allow for earlier—even fetal—intervention, particularly
for patients with IAS or RAS.24 Measures to delay preterm
delivery in appropriate cases to maximize in utero growth
and development might be warranted.
Longer term follow-up with larger patient numbers is
also necessary to determine whether more optimal out-
comes might be obtained with primary transplantation,
remembering the scarcity of donor hearts, particularly in
the neonatal/infant population.25 Finally, the role of hybrid
stage 1 palliation in the management of usual-risk patients
with HLHS and its variants remains to be defined, espe-
cially because the results of conventional surgical manage-
ment continue to improve.
Study Limitations
The limitations of the present study included those inher-
ent to a retrospective nonrandomized analysis at a single212 The Journal of Thoracic and Cardiovascular Surginstitution with respect to the relatively small number of
patients, heterogeneous patient population, and inherent
institutional bias with respect to critical care, interventional,
and operative management strategies.CONCLUSIONS
Bilateral PA banding and maintenance of ductal patency
with either DS or PGE1 is an effective method of resuscita-
tion for ‘‘high-risk’’ SV neonates and infants. This strategy
allows for reasonable survival to either conventional Nor-
wood palliation or primary transplantation, when appropri-
ate. DS in the presence of a diminutive ascending aorta
could compromise coronary perfusion and should be
avoided. Branch PA intervention ismore frequent in patients
requiring banding for longer periods. Early conventional
Norwood palliation is therefore optimal when possible,
and a thorough assessment of branch PAs must be under-
taken at transplantation. A birth weight less than 2.5 kg con-
tinues to be a significant risk factor for in-hospital death.References
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Dr Thomas Yeh (New Orleans, La). I would like to thank
Dr Guleserian for sending me the report last week and the Associ-
ation for the privilege of commenting on it.
I enjoyed reading it and commend you on your efforts to learn
from this, what is clearly a challenging group of patients, judging
by the amount of timeweall continue to spend on it. A fewquestions.
Because you have attempted to characterize the course of recov-
ery with rescue banding, did you consider including a control
group of conventional Norwood procedures for comparison?
Dr Guleserian.We did look back at our conventional Norwood
mortality during the same time period. Of the 80 conventional
Norwood procedures performed, overall mortality was 13.6% in-
cluding those with presence of an extracardiac syndromes. I do not
have data in terms of the hemodynamics, the fluid balance, and so
forth, for that usual Norwood group in comparison to the PA
banded group to answer your specific question.
Dr Yeh. I realize this was a retrospective study, but what were
your specific criteria in Dallas for using this approach and have
they changed now as a result of your analysis here?
Dr Guleserian. That is a very good and key question. Any time
we encountered a patient with severe ventricular dysfunction, sig-
nificant AVVR, or IAS or RAS high-risk group, we considered
them to be high risk and suitable candidates for bilateral PA band-
ing. Additionally, if a patient presented with renal insufficiency,
renal failure, or any other end-organ dysfunction that was notThe Journal of Thoracic and Caimmediately reversed with inotropic support and/or ventilatory
changes, we would identify those patients as candidates for band-
ing. We tend to use ductal stenting less commonly if we think
that therewill be rapid hemodynamic recovery in response to band-
ing and thus be candidates for conventional Norwood pathway. For
those whom we have identified as patients who do not seem like
they are on that road to hemodynamic recovery, DS is undertaken.
Dr Yeh. After PAB was performed, you had several approaches
to the patients, including completion Norwood rather than the
comprehensive stage 2, which you commented on briefly. What
was your algorithm for a given approach (ie, DS vs prostaglandins
and, more importantly, Norwood vs CS2)? I am going to ask you
the same question Chris just asked, because some would argue
that having stabilized the patient with the hybrid stage 1.
Dr Guleserian. Why rock the boat.
Dr Yeh..Why subject the patient to the additive risk of a Nor-
wood rather than waiting for the comprehensive stage 2?
Dr Guleserian.As an institution, our bias has been toward con-
ventional Norwood. We really do not perform the CS2 procedure
given poor results with such high-risk patients. We find that if we
can rapidly turn these patients around that conventional Norwood
operation is preferred to avoid the long-term pulmonary artery
problems we have seen with long-term banded patients. For the pa-
tients who do not turn around—the ones for whom primary trans-
plantation may be the most suitable option—we would pursue DS
and discontinue prostaglandin therapy.
DrYeh.But since your original hypothesis was not met with the
equivalent mortality, perhaps that is an option to consider.
Dr Guleserian. In response to your question about whether we
have changed any of our management strategy: I think for patients,
for example, who are extremely tiny and premature, as was one of
our patients who was only 900 g, and a former 27-week-old neo-
nate, the likelihood is that they are probably not going to do
well. For these very high-risk patients who are extremely prema-
ture, have low birth weight, and have a small ascending aortas,
we will likely still try to support these patients but avoid DS
with the potential for coronary ischemia. I think that this group
is best termed the worst of the worst.
Dr Yeh. Finally, in your data, unfortunately, children weighing
less than 2.5 kg did not benefit from this approach, because the
mortality was 100%, a consistent risk factor that Drs Bacha and
Barron actually highlighted for us over the weekend. Have you
looked into the clinical behavior of that group in the perioperative
period to see whether they differ fundamentally from the patients
weighing more than 2.5 kg? Do they behave differently? Is there
something special about that group that you are noticing?
Dr Guleserian. I think the special or unique part of that partic-
ular group is that they have other significant risk factors. It is not
just the weight. They were also the ones with a gestational age
that are in the low 30s. In this specific group, 2 of the 4 neonates
were the ones with diminutive ascending aorta and I think that
our approach with DS was wrong and we should have just left
them on prostaglandins. I do not know if the outcomewould be dif-
ferent. But that is something that we have learned to avoid for the
tiniest patients with a diminutive ascending aorta.
Dr Yeh. Thanks. I enjoyed reading the report.
Dr Christopher A. Caldarone (Toronto, Ontario, Canada).
Kristine, 3 patients died, I believe, during the procedure. Two ofrdiovascular Surgery c Volume 145, Number 1 213
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Dthem were pretty small. Had you deployed the DS at that point or
were those patients continued with prostaglandins?
Dr Guleserian. Actually, 2 of the 3 had DSs placed. All 3
patients made it out of the operating room but they did not spend
a lot of time alive out of the operating room. There were 2 patients
who had DSs deployed at the time of banding, and I think that was
probably an error given their diminutive ascending aortas. The
third patient was a former 33-week-old, 1.8-kg patient who had
received multiple doses of surfactant after delivery and got into
a respiratory acidosis cycle that we could not get him out of.
Dr Caldarone.Well, I would just make 2 comments about that.
In our experience, bPAB is associated with an acute bump in after-
load for these hearts, and we found that they need a fair amount of
inotropic support. Also, providing that up front rather than waiting
for it to become apparent has been helpful. Also I think that is even
more apparent in the smaller neonates.
The other issue is this issue of reverse Blalock-Taussig shunts.
If these patients have events shortly after deploying of the DS, one214 The Journal of Thoracic and Cardiovascular Surgmust be worried that they had acute retrograde arch malperfusion.
If that is the case, you have a choice. You can either treat it or you
can try to prevent it. So, in Toronto, we use a preventive approach,
which might have its own set of problems, but creates an alterna-
tive source of perfusion to the aortic arch and renders the isthmus
area redundant. The alternative is to use a treatment approach.
But, as you have found, it is very hard to treat these patients after
they have developed acute compromise of retrograde arch
perfusion.
Dr Guleserian. I would agree. And I think we are quite aggres-
sive about afterload reduction. It is not unusual for us to give a dose
of phentolamine and then initiate high-dose milrinone therapy
pretty quickly. Many of these patients are coming to the operating
room on pretty high-dose ‘‘rocket fuel’’ so to speak, so they are
a very tenous group. I think all of the efforts that your group,
and efforts from the experience that we just heard about in the pre-
vious presentation, will help some of these very high-risk patients
make it when they might not otherwise.ery c January 2013
